Medexus Pharmaceuticals (CVE:MDP) Lowered to Market Perform at Raymond James

Raymond James downgraded shares of Medexus Pharmaceuticals (CVE:MDPGet Rating) from an outperform rating to a market perform rating in a research report released on Tuesday, BayStreet.CA reports. The brokerage currently has C$2.00 price objective on the stock, down from their previous price objective of C$4.50.

Separately, Stifel Nicolaus decreased their price target on shares of Medexus Pharmaceuticals from C$14.25 to C$11.00 in a research report on Wednesday, August 10th.

Medexus Pharmaceuticals Price Performance

Shares of CVE:MDP opened at C$7.75 on Tuesday. The company has a market cap of C$148.54 million and a price-to-earnings ratio of -4.28. The company has a debt-to-equity ratio of 1,174.36, a current ratio of 1.19 and a quick ratio of 0.74. The firm has a 50 day simple moving average of C$7.75 and a 200 day simple moving average of C$7.75. Medexus Pharmaceuticals has a one year low of C$2.80 and a one year high of C$9.75.

About Medexus Pharmaceuticals

(Get Rating)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.

Featured Stories

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.